In short
This article discusses the ongoing clinical trials investigating the use of NKT2152, also known as 3-Fluoro-5-{[(2Ar,4S)-1,1,2,2,4-Pentafluoro-2A-Hydroxy-2,2A,3,4-Tetrahydro-1H-Cyclopenta[Cd]Inden-5-Yl]Oxy}Benzonitrile, in patients with advanced liver cancers. The drug is being studied as part of a larger Phase Ib/II clinical trial called MORPHEUS-Liver, which aims to evaluate the efficacy and safety of various immunotherapy-based treatment combinations. NKT2152 is a small molecule HIF2α inhibitor that is being tested in combination with other treatments to potentially improve outcomes for patients with advanced liver cancer.
At a glance
- Study Type
- Phase Ib/II, open-label, multicenter, randomized umbrella study
- Target Condition
- Advanced liver cancers (hepatocellular carcinoma)
- Main Objective
- Evaluate efficacy and safety of immunotherapy-based treatment combinations
- Primary Endpoints
- Objective response rate (ORR), safety assessment
- Key Eligibility Criteria
- Adults with advanced HCC, no prior systemic treatment, Child-Pugh class A
- NKT2152 Information
- Small molecule HIF2α inhibitor, administered orally as hard capsules
- Study Design
- Multiple treatment arms, flexible to add or close arms based on results
What is NKT2152?
NKT2152 is a new medication being studied for the treatment of advanced liver cancer. It's also known by its scientific name, which is quite long: 3-fluoro-5-{[(2ar,4s)-1,1,2,2,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-5-yl]oxy}benzonitrile. The medication is taken orally in the form of a hard capsule.
How does NKT2152 work?
NKT2152 is classified as a small molecule HIF2α inhibitor. This means it targets a specific protein in cancer cells called HIF2α. HIF2α plays a role in helping cancer cells survive and grow, especially in low-oxygen conditions. By blocking this protein, NKT2152 aims to slow down or stop the growth of liver cancer cells.
Clinical Trial Information
NKT2152 is currently being studied in a clinical trial called MORPHEUS-LIVER. This is a Phase Ib/II study, which means it's testing both the safety and effectiveness of the drug. The trial is specifically looking at NKT2152 in combination with other cancer treatments for patients with advanced liver cancer.
Who can participate in the trial?
The trial is looking for patients with specific characteristics. Here are some of the main criteria:
- Adults aged 18 or older
- Diagnosed with advanced liver cancer (specifically hepatocellular carcinoma or HCC) that can't be treated with surgery
- Have not received any previous systemic treatment for their liver cancer
- Are in relatively good health overall (able to carry out daily activities with minimal assistance)
There are also some reasons why a person might not be able to participate, such as having certain other medical conditions or having received specific treatments in the past.
What to expect during the trial
If you participate in this trial, you may receive NKT2152 in combination with other cancer treatments. The study is designed to compare different treatment combinations to see which works best. You'll be randomly assigned to one of several treatment groups.
Throughout the study, doctors will monitor your health closely. They'll be looking at several things:
- How well the treatment is working to shrink or control your cancer
- Any side effects you might experience
- How long the treatment keeps working
- How the treatment affects your overall survival
The doctors will use various tests, including scans and blood tests, to keep track of these factors.
Potential benefits of NKT2152
While it's important to remember that NKT2152 is still being studied and its benefits are not yet proven, researchers hope it might offer several advantages:
- A new option for patients with advanced liver cancer who haven't had other treatments
- Potential to slow down or stop the growth of liver cancer
- Possibility of working well in combination with other cancer treatments
- Convenience of being taken orally as a capsule, rather than requiring injections or infusions
However, like all medications, NKT2152 may also have side effects. The ongoing clinical trial will help researchers better understand both the benefits and risks of this new treatment.